178 related articles for article (PubMed ID: 33619057)
1. Drug susceptibility distributions of
Schulthess B; Schäfle D; Kälin N; Widmer T; Sander P
Antimicrob Agents Chemother; 2023 May; 65(5):. PubMed ID: 33619057
[TBL] [Abstract][Full Text] [Related]
2. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex.
Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K
Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595
[TBL] [Abstract][Full Text] [Related]
3. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
5. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates.
Mok S; Hannan MM; Nölke L; Stapleton P; O'Sullivan N; Murphy P; McLaughlin AM; McNamara E; Fitzgibbon MM; Rogers TR
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262760
[No Abstract] [Full Text] [Related]
7. Antimicrobial Susceptibility Testing Using the MYCO Test System and MIC Distribution of 8 Drugs against Clinical Isolates of Nontuberculous Mycobacteria from Shanghai.
Ying R; Yang J; Wu X; Yu F; Sha W
Microbiol Spectr; 2023 Feb; 11(2):e0254922. PubMed ID: 36802218
[TBL] [Abstract][Full Text] [Related]
8. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].
Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S
Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634
[TBL] [Abstract][Full Text] [Related]
9.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
10. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
11. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
12. Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach.
Cantillon D; Goff A; Taylor S; Salehi E; Fidler K; Stoneham S; Waddell SJ
Lancet Microbe; 2022 May; 3(5):e382-e391. PubMed ID: 35544099
[TBL] [Abstract][Full Text] [Related]
13. Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China.
Li Y; Liu C; Ma A; He W; Qiu Q; Zhao Y; Li Y
J Glob Antimicrob Resist; 2022 Dec; 31():90-97. PubMed ID: 35660663
[TBL] [Abstract][Full Text] [Related]
14. Differences in Drug-Susceptibility Patterns between
Fernandez-Pittol M; Batista-Arnau S; Román A; San Nicolás L; Oliver L; González-Moreno O; Martínez JA; Amaro-Rodríguez R; Soler N; Gené A; González-Cuevas A; Tudó G; Gonzalez-Martin J
Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671265
[No Abstract] [Full Text] [Related]
15.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
16. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.
Schön T; Chryssanthou E
Int J Infect Dis; 2017 Feb; 55():122-124. PubMed ID: 28069470
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
18. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles.
Truden S; Žolnir-Dovč M; Sodja E; Starčič Erjavec M
Infect Genet Evol; 2020 Aug; 82():104311. PubMed ID: 32247868
[TBL] [Abstract][Full Text] [Related]
19. Automated quantitative drug susceptibility testing of non-tuberculous mycobacteria using MGIT 960/EpiCenter TB eXiST.
Lucke K; Hombach M; Friedel U; Ritter C; Böttger EC
J Antimicrob Chemother; 2012 Jan; 67(1):154-8. PubMed ID: 21965431
[TBL] [Abstract][Full Text] [Related]
20. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran.
Daneshfar S; Khosravi AD; Hashemzadeh M
PLoS One; 2022; 17(8):e0267320. PubMed ID: 35960778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
